How to Dose AOD-9604: What the Research Actually Shows

AOD-9604 has no officially established human dose. The peptide is not FDA-approved for any human use, so the only dose information that exists comes from a small number of clinical trials and from laboratory handling notes. In those published studies, AOD-9604 was given as a once-daily subcutaneous injection, most often at about 1 mg per day.

This guide covers what the research literature reports, how dose math works after reconstitution, and where the safety and legal boundaries sit. It is informational only and is not medical advice.

What AOD-9604 Is and Why No Standard Dose Exists

AOD-9604 is a modified fragment of human growth hormone that corresponds to amino acids 176–191 of the full hormone. It was developed in the 1990s as a candidate treatment for obesity and metabolic conditions, based on the theory that the fragment could influence fat metabolism without the growth-promoting and blood-sugar effects of full growth hormone.

That development program never produced an approved medicine. Human trials showed only modest and inconsistent changes in body weight, and the compound was not approved by any regulator. No published human trial has established an effective dose of AOD-9604.

What exists instead is a small set of published studies plus a large, loosely regulated market of vials sold as research chemicals and labeled "not for human consumption." AOD-9604 is not FDA-approved for human use in the United States.

Doses Reported in Published Human Research

In the human studies that have been published, AOD-9604 was given by subcutaneous injection, generally once per day. The most commonly cited dose is approximately 1 mg per day, and the obesity trials typically ran for around 12 weeks.

Source of dosing information	Reported amount	Route and frequency	Strength of evidence
Published clinical trials	About 1 mg per day	Subcutaneous, once daily	Short-term safety data; modest effects on weight
Early tolerability and dose-ranging work	Single doses above 1 mg	Subcutaneous, escalating single doses	Tolerability only; no efficacy conclusion
Anecdotal user protocols	Roughly 250–500 mcg per injection	Subcutaneous, once or twice daily	No controlled data; unverified and highly variable

The trials did not show dramatic weight loss, which is the main reason AOD-9604 was never approved as a drug. Early tolerability studies reportedly tested single doses higher than the 1 mg daily figure, but those trials were designed to check safety rather than to identify a therapeutic dose.

Anyone comparing notes on how to use aod 9604 should treat trial doses and internet protocol doses as two very different categories of information.

How to Calculate a Dose After Reconstitution

Most AOD-9604 sold online is a lyophilized powder in a sealed vial, which means the amount you draw depends entirely on how much liquid was added. Two vials of identical size can end up at very different concentrations.

The underlying math is simple: concentration equals total peptide divided by total diluent volume. A 5 mg vial mixed with 2 mL of liquid gives 2.5 mg per mL, or 2,500 mcg per mL, so 1 mg equals 0.4 mL. A 10 mg vial mixed with 2 mL gives 5 mg per mL, so 1 mg equals 0.2 mL.

Vial size	Diluent added	Concentration	Volume for 1 mg	Volume for 300 mcg
5 mg	1 mL	5 mg/mL (5,000 mcg/mL)	0.20 mL	0.06 mL
5 mg	2 mL	2.5 mg/mL (2,500 mcg/mL)	0.40 mL	0.12 mL
10 mg	2 mL	5 mg/mL (5,000 mcg/mL)	0.20 mL	0.06 mL
10 mg	3 mL	3.3 mg/mL (3,333 mcg/mL)	0.30 mL	0.09 mL

AOD-9604 dissolves poorly in plain water, so laboratory protocols commonly start with a small volume of dilute acetic acid and then top up with bacteriostatic water. A standard laboratory approach for how to reconstitute aod 9604 with acetic acid is to add the acetic acid first, swirl gently until the powder goes into solution, and then dilute to the final volume.

The arithmetic does not change with vial size. Working out how to reconstitute aod 9604 10mg follows exactly the same steps as a 5 mg vial; only the numbers in the table change.

Whatever method you use to mix aod-9604, avoid shaking the vial. Vigorous agitation can damage peptide structure, and a cloudy solution usually means the powder has not fully dissolved.

Injection Frequency and Timing

Published human trials used once-daily dosing, and that is the only frequency supported by clinical data. Anecdotal protocols sometimes split the total into two smaller injections, but no study has compared split dosing with a single daily injection.

Wondering how often to take aod 9604 is really a question about the total weekly amount rather than the number of injections. Doubling the number of shots does not change the weekly total unless the amount per injection is also reduced.

There is no published human evidence that injection timing around meals changes results. Some laboratory work suggests insulin may blunt the lipolytic effect of the fragment, which is why some people inject in a fasted state, but that idea has not been confirmed in human trials.

Safety, Legal Status, and Quality Concerns

AOD-9604 has been studied in humans only in short, relatively small trials, so its long-term safety profile is unknown. Reported side effects in those trials were generally mild and included injection-site reactions, headache, and nausea.

• Regulatory status: AOD-9604 is not approved by the FDA or any comparable agency for human use, and products sold online are legally marketed as research chemicals.
• No human-use data: There is no safety information for pregnancy, breastfeeding, children, or people with chronic health conditions.
• Purity risk: Research-chemical vials are not held to pharmaceutical manufacturing standards, so actual content and sterility can vary between vendors and batches.
• Unknown interactions: No formal interaction studies exist, including with diabetes medications, growth hormone, or thyroid drugs.

Anyone with a medical question about weight, metabolism, or hormone therapy should speak with a licensed healthcare professional rather than rely on research-chemical dosing information.

Common Dosing Mistakes to Avoid

1. Treating a trial dose as an official dose. No regulator has ever set an AOD-9604 dose for humans.
2. Confusing milligrams with micrograms. One milligram equals 1,000 micrograms, and mixing the two creates a tenfold error.
3. Copying a dose without checking the vial concentration. The same injection volume delivers different amounts from different vials.
4. Using plain water for a peptide that needs acetic acid to dissolve.
5. Ignoring vendor documentation. A certificate of analysis from a third-party lab is the only meaningful purity check available.

The bottom line: AOD-9604 dosing is guesswork dressed up as protocol. The only figure with human data behind it is roughly 1 mg once daily in short trials, and even that dose did not produce convincing weight-loss results.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical AOD-9604 dose per day?

Published human trials most commonly used about 1 mg per day given as a subcutaneous injection, usually for roughly 12 weeks. No regulator has approved AOD-9604, so there is no official dose and no standard protocol. Anecdotal protocols often use much smaller amounts that have never been tested in controlled studies.

Do you have to inject AOD-9604, or can you take it by mouth?

Every published human study of AOD-9604 used subcutaneous injection. Peptide fragments like this one are broken down by digestive enzymes, so oral bioavailability is poor and no oral form has been tested or approved. There is no evidence that oral or nasal AOD-9604 works.

Is AOD-9604 legal to buy in the United States?

AOD-9604 is not FDA-approved for human use and is not a prescription drug. It is sold online as a research chemical labeled "not for human consumption," which places it in a gray area of US law. Rules on personal importation and possession vary, and buyers assume the quality and safety risks themselves.